Skip to main content

Main menu

  • HOME
  • ARTICLES
    • Current Issue
    • Abstracts In Press
    • Archives
    • Special Issue Archive
    • Subject Collections
  • INFO FOR
    • Authors
    • Reviewers
    • Call For Papers
    • Subscribers
    • Advertisers
  • SUBMIT
    • Manuscript
    • Peer Review
  • ABOUT
    • The JABFM
    • The Editing Fellowship
    • Editorial Board
    • Indexing
    • Editors' Blog
  • CLASSIFIEDS
  • Other Publications
    • abfm

User menu

Search

  • Advanced search
American Board of Family Medicine
  • Other Publications
    • abfm
American Board of Family Medicine

American Board of Family Medicine

Advanced Search

  • HOME
  • ARTICLES
    • Current Issue
    • Abstracts In Press
    • Archives
    • Special Issue Archive
    • Subject Collections
  • INFO FOR
    • Authors
    • Reviewers
    • Call For Papers
    • Subscribers
    • Advertisers
  • SUBMIT
    • Manuscript
    • Peer Review
  • ABOUT
    • The JABFM
    • The Editing Fellowship
    • Editorial Board
    • Indexing
    • Editors' Blog
  • CLASSIFIEDS
  • JABFM on Bluesky
  • JABFM On Facebook
  • JABFM On Twitter
  • JABFM On YouTube
Research ArticleOriginal Research

Statin Therapy as Primary Prevention in Exercising Adults: Best Evidence for Avoiding Myalgia

N. John Bosomworth
The Journal of the American Board of Family Medicine November 2016, 29 (6) 727-740; DOI: https://doi.org/10.3122/jabfm.2016.06.160085
N. John Bosomworth
From the Department of Family Practice, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.
MD, CCFP
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
Loading

References

  1. 1.↵
    1. Stone NJ,
    2. Robinson JG,
    3. Lichtenstein AH,
    4. et al
    ; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63(25 Pt B):2889–934.
    OpenUrlFREE Full Text
  2. 2.↵
    1. Downs JR,
    2. O'Malley PG
    . Management of dyslipidemia for cardiovascular disease risk reduction: synopsis of the 2014 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline. Ann Intern Med 2015;163:291–7.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Anderson TJ,
    2. Grégoire J,
    3. Hegele RA,
    4. et al
    . 2012 Update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol 2013;29:151–67.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Han BH,
    2. Weinberger Y,
    3. Sutin D
    . Statinopause. J Gen Intern Med 2014;29:1702–6.
    OpenUrl
  5. 5.↵
    1. Mihaylova B,
    2. Emberson J,
    3. Blackwell L,
    4. et al
    . The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012;380:581–90.
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    1. Savarese G,
    2. Gotto AM,
    3. Paolillo S,
    4. et al
    . Benefits of statins in elderly subjects without established cardiovascular disease: a meta-analysis. J Am Coll Cardiol 2013;62:2090–9.
    OpenUrlFREE Full Text
  7. 7.↵
    1. Afilalo J,
    2. Duque G,
    3. Steele R,
    4. Jukema JW,
    5. de Craen AJM,
    6. Eisenberg MJ
    . Statins for secondary prevention in elderly patients: a hierarchical Bayesian meta-analysis. J Am Coll Cardiol 2008;51:37–45.
    OpenUrlFREE Full Text
  8. 8.↵
    1. Soran H,
    2. Schofield JD,
    3. Durrington PN
    . Cholesterol, not just cardiovascular risk, is important in deciding who should receive statin treatment. Eur Heart J 2015;36:2975–83.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Rose G
    . Sick individuals and sick populations. Bull World Health Organ 2001;79:990–6.
    OpenUrlPubMedWeb of Science
  10. 10.↵
    1. Zulman DM,
    2. Vijan S,
    3. Omenn GS,
    4. Hayward RA
    . The relative merits of population-based and targeted prevention strategies. Milbank Q 2008;86:557–80.
    OpenUrlCrossRefPubMedWeb of Science
  11. 11.↵
    1. Ioannidis JPA
    . More than a billion people taking statins? Potential implications of the new cardiovascular guidelines. JAMA 2013;94305:463–4.
    OpenUrl
  12. 12.↵
    1. Powers Hannley P
    . Move more, eat less: it's time for Americans to get serious about exercise. Am J Med 2014;127:681–4.
    OpenUrl
  13. 13.↵
    1. Pleis JR,
    2. Ward BW,
    3. Lucas JW
    . Summary health statistics for U.S. adults: National Health Interview Survey, 2009. Vital Health Stat 10 2010; 249:1–207.
    OpenUrl
  14. 14.↵
    1. Running USA
    . Running USA's annual marathon report. March 23, 2014. Available from: http://www.runningusa.org/index.cfm?fuseaction=news.details&ArticleId=332&returnTo=annual-reports. Accessed February 18, 2016.
  15. 15.↵
    1. Zingg M,
    2. Rüst CA,
    3. Lepers R,
    4. Rosemann T,
    5. Knechtle B
    . Master runners dominate 24-h ultramarathons worldwide-a retrospective data analysis from 1998 to 2011. Extrem Physiol Med 2013;2:21.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Harper CR,
    2. Jacobson TA
    . Evidence-based management of statin myopathy. Curr Atheroscler Rep 2010;12:322–30.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Fernandez G,
    2. Spatz ES,
    3. Jablecki C,
    4. Phillips PS
    . Statin myopathy: a common dilemma not reflected in clinical trials. Cleve Clin J Med 2011;78:393–403.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Bruckert E,
    2. Hayem G,
    3. Dejager S,
    4. Yau C,
    5. Bégaud B
    . Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients–the PRIMO study. Cardiovasc Drugs Ther 2005;19:403–14.
    OpenUrlCrossRefPubMedWeb of Science
  19. 19.↵
    1. Sofi F,
    2. Capalbo A,
    3. Cesari F,
    4. Abbate R,
    5. Gensini GF
    . Physical activity during leisure time and primary prevention of coronary heart disease: an updated meta-analysis of cohort studies. Eur J Cardiovasc Prev Rehabil 2008;15:247–57.
    OpenUrlCrossRefPubMedWeb of Science
  20. 20.↵
    1. Hamer M,
    2. Chida Y
    . Walking and primary prevention: a meta-analysis of prospective cohort studies. Br J Sports Med 2008;42:238–43.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Kokkinos PF,
    2. Faselis C,
    3. Myers J,
    4. Panagiotakos D,
    5. Doumas M
    . Interactive effects of fitness and statin treatment on mortality risk in veterans with dyslipidaemia: a cohort study. Lancet 2013;381:394–9.
    OpenUrlCrossRefPubMedWeb of Science
  22. 22.↵
    1. Ebell MH,
    2. Siwek J,
    3. Weiss BD,
    4. et al
    . Strength of recommendation taxonomy (SORT): a patient-centered approach to gathering evidence in the medical literature. J Am Board Fam Pract 2004;17:59–67.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Mancini GBJ,
    2. Tashakkor AY,
    3. Baker S,
    4. et al
    . Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian working group consensus update. Can J Cardiol 2013;29:1553–68.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Rosenson RS,
    2. Baker SK,
    3. Jacobson TA,
    4. Kopecky SL,
    5. Parker BA
    . An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol 2014;8:S58–71.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Pasternak RC,
    2. Smith SC Jr.,
    3. Bairey-Merz CN,
    4. Grundy SM,
    5. Cleeman JI,
    6. Lenfant C
    ; American College of Cardiology; American Heart Association; National Heart, Lung and Blood Institute. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Am Coll Cardiol 2002;40:1024–8.
    OpenUrl
  26. 26.↵
    1. Clarkson PM,
    2. Hubal MJ
    . Exercise-induced muscle damage in humans. Am J Phys Med Rehabil 2002;81(11 Suppl):S52–69.
    OpenUrlCrossRefPubMedWeb of Science
  27. 27.↵
    1. Phillips PS,
    2. Haas RH,
    3. Bannykh S,
    4. et al
    . Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2002;137:581–5.
    OpenUrlCrossRefPubMedWeb of Science
  28. 28.↵
    1. Draeger A,
    2. Monastyrskaya K,
    3. Mohaupt M,
    4. et al
    . Statin therapy introduces ultrastructural damage in skeletal muscle in patients without myalgia. J Pathol 2006;210:94–102.
    OpenUrlCrossRefPubMedWeb of Science
  29. 29.↵
    1. Thompson PD,
    2. Zmuda JM,
    3. Domalik LJ,
    4. Zimet RJ,
    5. Staggers J,
    6. Guyton JR
    . Lovastatin increases exercise-induced skeletal muscle injury. Metabolism 1997;46:1206–10.
    OpenUrlCrossRefPubMedWeb of Science
  30. 30.↵
    1. Taylor BA,
    2. Lorson L,
    3. White CM,
    4. Thompson PD
    . A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy. Atherosclerosis 2015;238:329–35.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Skarlovnik A,
    2. Janić M,
    3. Lunder M,
    4. Turk M,
    5. Šabovič M
    . Coenzyme Q10 supplementation decreases statin-related mild-to-moderate muscle symptoms: a randomized clinical study. Med Sci 2014;20:2183–8.
    OpenUrl
  32. 32.↵
    1. Tomaszewski M,
    2. Stêpieñ KM,
    3. Tomaszewska J,
    4. Czuczwar SJ
    . Statin-induced myopathies. Pharmacol Rep 2011;63:859–66.
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Urso ML
    . Changes in ubiquitin proteasome pathway gene expression in skeletal muscle with exercise and statins. Arterioscler Thromb Vasc Biol 2005;25:2560–6.
    OpenUrlAbstract/FREE Full Text
  34. 34.↵
    1. Thompson PD,
    2. Clarkson P,
    3. Karas RH
    . Statin associated myopathy. JAMA 2003;289:1681–90.
    OpenUrlCrossRefPubMedWeb of Science
  35. 35.↵
    1. Kashani A,
    2. Phillips CO,
    3. Foody JM,
    4. et al
    . Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 2006;114:2788–197.
    OpenUrlAbstract/FREE Full Text
  36. 36.↵
    1. Jacobson TA
    . Toward “pain-free” statin prescribing: clinical algorithm for diagnosis and management of myalgia. Mayo Clin Proc 2008;83:687–700.
    OpenUrlCrossRefPubMedWeb of Science
  37. 37.↵
    1. Bulbulia R,
    2. Bowman L,
    3. Wallendszus K,
    4. et al
    . Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20 536 high-risk individuals: a randomised controlled trial. Lancet 2011;378:2013–20.
    OpenUrlCrossRefPubMedWeb of Science
  38. 38.↵
    1. McClure DL,
    2. Valuck RJ,
    3. Glanz M,
    4. Hokanson JE
    . Systematic review and meta-analysis of clinically relevant adverse events from HMG CoA reductase inhibitor trials worldwide from 1982 to present. Pharmacoepidemiol Drug Saf 2007;16:132–43.
    OpenUrlCrossRefPubMed
  39. 39.↵
    1. Tobert JA,
    2. Newman CB
    . Statin tolerability: in defence of placebo-controlled trials. Eur J Prev Cardiol 2016;23:891–6.
    OpenUrlAbstract/FREE Full Text
  40. 40.↵
    1. Parker BA,
    2. Capizzi JA,
    3. Grimaldi AS,
    4. et al
    . Effect of statins on skeletal muscle function. Circulation 2013;127:96–103.
    OpenUrlAbstract/FREE Full Text
  41. 41.↵
    1. Macedo A,
    2. Taylor F,
    3. Casas JP,
    4. Adler A,
    5. Prieto-Merino D,
    6. Ebrahim S
    . Unintended effects of statins from observational studies in the general population: systematic review and meta-analysis. BMC Med 2014;12:51.
    OpenUrlCrossRefPubMed
  42. 42.↵
    1. Stroes ES,
    2. Thompson PD,
    3. Corsini A,
    4. et al
    . Statin-associated muscle symptoms: impact on statin therapy–European Atherosclerosis Society Consensus Panel statement on assessment aetiology and management. Eur Heart J 2015;36:1012–22.
    OpenUrlAbstract/FREE Full Text
  43. 43.↵
    1. Sinzinger H,
    2. O'Grady J
    . Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems. Br J Clin Pharmacol 2004;57:525–8.
    OpenUrlCrossRefPubMedWeb of Science
  44. 44.↵
    1. Lee D-C,
    2. Pate RR,
    3. Lavie CJ,
    4. Sui X,
    5. Church TS,
    6. Blair SN
    . Leisure-time running reduces all-cause and cardiovascular mortality risk. J Am Coll Cardiol 2014;64:472–81.
    OpenUrlFREE Full Text
  45. 45.↵
    1. Williams PT,
    2. Thompson PD
    . Effects of statin therapy on exercise levels in participants in the National Runners' and Walkers' Health Study. Mayo Clin Proc 2015;90:1338–47.
    OpenUrlCrossRefPubMed
  46. 46.↵
    1. Panza GA,
    2. Taylor BA,
    3. Thompson PD,
    4. et al
    . The effect of atorvastatin on habitual physical activity among healthy adults. Med Sci Sports Exerc 2015;48:1–6.
    OpenUrl
  47. 47.
    1. Golomb BA,
    2. Evans MA,
    3. Dimsdale JE,
    4. White HL
    . Effects of statins on energy and fatigue with exertion: results from a randomized controlled trial. Arch Intern Med 2012;172:1180–2.
    OpenUrlPubMedWeb of Science
  48. 48.
    1. Mikus CR,
    2. Boyle LJ,
    3. Borengasser SJ,
    4. et al
    . Simvastatin impairs exercise training adaptations. J Am Coll Cardiol 2013;62:709–14.
    OpenUrlFREE Full Text
  49. 49.
    1. Scott D,
    2. Blizzard L,
    3. Fell J,
    4. Jones G
    . Statin therapy, muscle function and falls risk in community-dwelling older adults. QJM 2009;102:625–33.
    OpenUrlAbstract/FREE Full Text
  50. 50.
    1. Qureshi WT,
    2. Keteyian SJ,
    3. Brawner CA,
    4. Dardari Z,
    5. Blaha MJ,
    6. Al-Mallah MH
    . Impact of statin use on cardiorespiratory fitness in multi-racial men and women: the Henry Ford Exercise Testing (FIT) Project. Int J Cardiol 2015;197:76–7.
    OpenUrl
  51. 51.
    1. Lee DS,
    2. Markwardt S,
    3. Goeres L,
    4. et al
    . Statins and physical activity in older men: the Osteoporotic Fractures in Men Study. JAMA Intern Med 2014;174:1263–70.
    OpenUrlCrossRefPubMed
  52. 52.
    1. Terpak K,
    2. Guthrie S,
    3. Erickson S
    . Statin use and self-reported swimming performance in US masters swimmers. J Sports Sci 2015;33:286–92.
    OpenUrl
  53. 53.↵
    1. Cham S,
    2. Evans MA,
    3. Denenberg JO,
    4. Golomb BA
    . Statin-associated muscle-related adverse effects: a case series of 354 patients. Pharmacotherapy 2010;30:541–53.
    OpenUrlCrossRefPubMed
  54. 54.↵
    1. Ridker PM,
    2. Rose L,
    3. Cook R
    . A proposal to incorporate trial data into a hybrid ACC/AHA algorithm for the allocation of statin therapy in primary prevention. J Am Coll Cardiol 2015;65:942–8.
    OpenUrlFREE Full Text
  55. 55.↵
    1. Glueck CJ,
    2. Rawal B,
    3. Khan NA,
    4. Yeramaneni S,
    5. Goldenberg N,
    6. Wang P
    . Should high creatine kinase discourage the initiation or continuance of statins for the treatment of hypercholesterolemia? Metabolism 2009;58:233–8.
    OpenUrlPubMed
  56. 56.↵
    1. Lenz TL
    . Are physically active individuals taking statins at increased risk for myopathy? Am J Lifestyle Med 2009;3:287–9.
    OpenUrlAbstract/FREE Full Text
  57. 57.↵
    1. Semple SJ
    . Statin therapy, myopathy and exercise - a case report. Lipids Health Dis 2012;11:40.
    OpenUrlPubMed
  58. 58.↵
    1. Evans WJ,
    2. Meredith CN,
    3. Cannon JG,
    4. et al
    . Metabolic changes following eccentric exercise in trained and untrained men. J Appl Physiol 1986;61:1864–8.
    OpenUrlAbstract/FREE Full Text
  59. 59.↵
    1. Bonfim MR,
    2. Oliveira ASB,
    3. do Amaral SL,
    4. Monteiro HL
    . Treatment of dyslipidemia with statins and physical exercises: recent findings of skeletal muscle responses. Arq Bras Cardiol 2015;324–32.
  60. 60.↵
    1. Kearns AK,
    2. Bilbie CL,
    3. Clarkson PM,
    4. et al
    . The creatine kinase response to eccentric exercise with atorvastatin 10mg or 80mg. Atherosclerosis 2008;200:121–5.
    OpenUrlPubMed
  61. 61.↵
    1. Josan K,
    2. Majumdar SR,
    3. McAlister FA
    . The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials. CMAJ 2008;178:576–84.
    OpenUrlAbstract/FREE Full Text
  62. 62.↵
    1. Ruisinger JF,
    2. Backes JM,
    3. Gibson CA,
    4. Moriarty PM
    . Once-a-week rosuvastatin (2.5 to 20 mg) in patients with a previous statin intolerance. Am J Cardiol 2009;103:393–4.
    OpenUrlCrossRefPubMed
  63. 63.↵
    1. Gadarla M,
    2. Kearns AK,
    3. Thompson PD
    . Efficacy of rosuvastatin (5 mg and 10 mg) twice a week in patients intolerant to daily statins. Am J Cardiol 2008;101:1747–8.
    OpenUrlCrossRefPubMedWeb of Science
  64. 64.↵
    1. Mampuya WM,
    2. Frid D,
    3. Rocco M,
    4. et al
    . Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience. Am Heart J 2013;166:597–603.
    OpenUrlCrossRefPubMedWeb of Science
  65. 65.↵
    1. Stein EA,
    2. Ballantyne CM,
    3. Windler E,
    4. et al
    . Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins. Am J Cardiol 2008;101:480–96.
    OpenUrl
  66. 66.↵
    1. Cannon CP,
    2. Blazing MA,
    3. Giugliano RP,
    4. et al
    . Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015;372:2387–97.
    OpenUrlCrossRefPubMed
  67. 67.↵
    1. Lee P,
    2. Greenfield JR,
    3. Campbell LV
    . Vitamin D insufficiency - a novel mechanism of statin-induced myalgia? Clin Endocrinol 2009;71:154–5.
    OpenUrlCrossRefPubMed
  68. 68.↵
    1. Michalska-Kasiczak M,
    2. Sahebkar A,
    3. Mikhailidis DP,
    4. et al
    ; Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. Analysis of vitamin D levels in patients with and without statin-associated myalgia - a systematic review and meta-analysis of 7 studies with 2420 patients. Int J Cardiol 2014;178:111–6.
    OpenUrlPubMed
  69. 69.↵
    1. Khayznikov M,
    2. Hemachrandra K,
    3. Pandit R,
    4. Kumar A,
    5. Wang P,
    6. Glueck CJ
    . Statin intolerance because of myalgia, myositis, myopathy or myonecrosis can in most cases be safely resolved by vitamin D supplementation. North Am J Med Sci 2015;7:86–93.
    OpenUrl
  70. 70.↵
    1. Banach M,
    2. Serban C,
    3. Sahebkar A,
    4. et al
    . Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. Mayo Clin Proc 2014;90:1–11.
    OpenUrl
  71. 71.↵
    1. Canner PL,
    2. Furberg CD,
    3. McGovern ME
    . Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol 2006;97:477–9.
    OpenUrlCrossRefPubMedWeb of Science
  72. 72.↵
    1. Tenkanen L,
    2. Mänttäri M,
    3. Mannien V
    . Some coronary risk factors related to insulin resistance syndrome and treatment with gemfibrozil. Circulation 1995;92:1779–85.
    OpenUrlAbstract/FREE Full Text
  73. 73.↵
    1. Magarian GJ,
    2. Lucas LM,
    3. Colley C
    . Gemfibrozil-induced myopathy. Arch Intern Med 1991;151:1873–4.
    OpenUrlCrossRefPubMedWeb of Science
  74. 74.↵
    1. Slim H,
    2. Thompson PD
    . Ezetimibe-related myopathy: a systematic review. J Clin Lipidol 2008;2:328–34.
    OpenUrlPubMed
  75. 75.↵
    1. Pandor A,
    2. Ara RM,
    3. Tumur I,
    4. et al
    . Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials. J Intern Med 2009;265:568–80.
    OpenUrlCrossRefPubMed
  76. 76.↵
    1. Robinson JG,
    2. Farnier M,
    3. Krempf M,
    4. et al
    . Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015;372:1489–99.
    OpenUrlCrossRefPubMed
  77. 77.
    1. Rivers SM,
    2. Kane MP,
    3. Busch RS,
    4. Bakst G,
    5. Hamilton RA
    . Colesevelam hydrochloride-ezetimibe combination lipid-lowering therapy in patients with diabetes or metabolic syndrome and a history of statin intolerance. Endocr Pract 2007;13:11–6.
    OpenUrlPubMed
  78. 78.↵
    1. Ford ES,
    2. Bergmann MM,
    3. Kröger J,
    4. Schienkiewitz A,
    5. Weikert C,
    6. Boeing H
    . Healthy living is the best revenge: findings from the European Prospective Investigation Into Cancer and Nutrition – Potsdam Study. Arch Intern Med 2009;169:1355–62.
    OpenUrlCrossRefPubMedWeb of Science
  79. 79.↵
    1. Opie LH
    . Exercise-induced myalgia may limit the cardiovascular benefits of statins. Cardiovasc Drugs Ther 2013;27:569–72.
    OpenUrlPubMed
  80. 80.↵
    1. Downs JR,
    2. Clearfield M,
    3. Weis S,
    4. et al
    . Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA 1998;279:1615–22.
    OpenUrlCrossRefPubMedWeb of Science
  81. 81.↵
    1. Nakamura H,
    2. Arakawa K,
    3. Itakura H,
    4. et al
    . Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 2006;368:1155–63.
    OpenUrlCrossRefPubMedWeb of Science
  82. 82.↵
    1. Ridker PM,
    2. Danielson E,
    3. Fonseca FAH,
    4. et al
    . Rosuvastatin to prevent vascular events in men and women with elevated c-reactive protein. N Engl J Med 2008;359:2195–207.
    OpenUrlCrossRefPubMedWeb of Science
  83. 83.↵
    1. Yusuf G,
    2. Bosch J,
    3. Dagenais G,
    4. et al
    . Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 2016;374:2021–31.
    OpenUrlCrossRefPubMed
  84. 84.↵
    1. Thavendiranathan P,
    2. Bagai A,
    3. Brookhard MA,
    4. Choudhry NK
    . Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. Arch Intern Med 2006;166:2307–13.
    OpenUrlCrossRefPubMedWeb of Science
  85. 85.↵
    1. Mills EJ,
    2. Rachlis B,
    3. Wu P,
    4. Devereaux PJ,
    5. Arora P,
    6. Perri D
    . Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol 2008;52:1769–81.
    OpenUrlFREE Full Text
  86. 86.↵
    1. Petretta M,
    2. Costanzo P,
    3. Perronne-Filardi P,
    4. Chiariello M
    . Impact of gender in primary prevention of coronary heart disease with statin therapy: a meta-analysis. Int J Cardiol 2010;138:25–31.
    OpenUrlCrossRefPubMedWeb of Science
  87. 87.
    1. Ray KK,
    2. Seshasai SRK,
    3. Erqou S,
    4. et al
    . Statins and all-cause mortality in high-risk primary prevention. Arch Intern Med 2010;170:1024–31.
    OpenUrlCrossRefPubMedWeb of Science
  88. 88.↵
    1. Mora S,
    2. Glynn RJ,
    3. Hsia J,
    4. MacFayden JG,
    5. Genest J,
    6. Ridker P
    . Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity c-reactive protein or dyslipidemia: results from the Justification for the Use of Statins for Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation 2010;121:1069–77.
    OpenUrlAbstract/FREE Full Text
  89. 89.↵
    1. Kostis WJ,
    2. Cheng JQ,
    3. Dobrzynski JM,
    4. Cabera J,
    5. Kostis JB
    . Meta-analyis of statin effects in women versus men. J Am Coll Cardiol 2012;59:572–82.
    OpenUrlFREE Full Text
  90. 90.↵
    1. Taylor F,
    2. Huffman MD,
    3. Macedo AF,
    4. et al
    . Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst 2013;(1):CD004816.
  91. 91.↵
    1. Brugts JJ,
    2. Yetgin T,
    3. Hoeks SE,
    4. et al
    . The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomized controlled trials. BMJ 2009;338:b2376.
    OpenUrlAbstract/FREE Full Text
  92. 92.↵
    1. Yan YL,
    2. Qiu B,
    3. Hu LJ,
    4. et al
    . Efficacy and safety evaluation of intensive statin therapy in older patients with coronary heart disease: a systematic review and meta-analysis. Eur J Clin Pharmacol 2013;69:2001–9.
    OpenUrlCrossRefPubMed
  93. 93.↵
    1. Cannon CP,
    2. Steinberg BA,
    3. Murphy SA,
    4. Mega JL,
    5. Braunwald E
    . Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 2006;48:438–45.
    OpenUrlFREE Full Text
  94. 94.↵
    1. Löllgen H,
    2. Böckenhoff A,
    3. Knapp G
    . Physical activity and all-cause mortality: an updated meta-analysis with different intensity categories. Int J Sports Med 2009;30:213–24.
    OpenUrlCrossRefPubMedWeb of Science
  95. 95.↵
    1. Nocon M,
    2. Hiemann T,
    3. Müller-Riemenschneider F,
    4. Thalau F,
    5. Roll S,
    6. Willich S
    . Association of physical activity with all-cause and cardiovascular mortality: a systematic review and meta-analysis. Eur J Cardiovasc Prev Rehabil 2008;15:239–46.
    OpenUrlCrossRefPubMedWeb of Science
  96. 96.
    1. Li J,
    2. Siegrist J
    . Physical activity and risk of cardiovascular disease - a meta-analysis of prospective cohort studies. Int J Environ Res Public Health 2012;9:391–407.
    OpenUrlCrossRefPubMed
  97. 97.
    1. Sattelmair J,
    2. Pertman J,
    3. Kohl HW III.,
    4. Haskell W,
    5. Lee I-M
    . Dose-response between physical activity and risk of coronary heart disease: a meta-analysis. Circulation 2011;124:789–95.
    OpenUrlAbstract/FREE Full Text
  98. 98.↵
    1. Colley RC,
    2. Garriguet D,
    3. Janssen I,
    4. Craig CL,
    5. Clarke J,
    6. Tremblay MS
    . Physical activity of Canadian adults: accelerometer results from the 2007 to 2009 Canadian Health Measures Survey. Health Rep 2011;22:7–14.
    OpenUrlPubMed
  99. 99.↵
    1. Naci H,
    2. Ioannidis JPA
    . Comparative effectiveness of exercise and drug interventions on mortality outcomes: metaepidemiological study. BMJ 2013;347:f5577.
    OpenUrlAbstract/FREE Full Text
  100. 100.↵
    1. Hupin D,
    2. Roche F,
    3. Gremeaux V,
    4. et al
    . Even a low-dose of moderate-to-vigorous physical activity reduces mortality by 22% in adults aged ≥60 years: a systematic review and meta-analysis. Br J Sports Med 2015;49:1262–7.
    OpenUrlAbstract/FREE Full Text
  101. 101.↵
    1. Chakravarty EF,
    2. Hubert HB,
    3. Lingala VB,
    4. Fries JF
    . Reduced disability and mortality among ageing runners: a 21-year longitudinal study. Arch Intern Med 2008;168:1638–46.
    OpenUrlCrossRefPubMedWeb of Science
  102. 102.↵
    1. Vos E,
    2. Rose CP,
    3. Biron P
    . Rebuttal: why statins have failed to reduce mortality in just about anybody. J Clin Lipidol 2013;7:228.
    OpenUrl
  103. 103.↵
    1. Tomlinson SS,
    2. Mangione KK
    . Potential adverse effects of statins on muscle. Phys Ther 2005;85:459–65.
    OpenUrlFREE Full Text
  104. 104.↵
    1. Soverow J,
    2. Watson K
    . Is there sufficient enhancement of the reduction in CVD rates after a decade of statin therapy to justify continuation? Curr Atheroscler Rep 2014;16:432.
    OpenUrl
  105. 105.↵
    1. Knowler WC,
    2. Barrett-Connor E,
    3. Fowler SE,
    4. et al
    ; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393–403.
    OpenUrlCrossRefPubMedWeb of Science
  106. 106.↵
    1. Cederberg H,
    2. Stancakova A,
    3. Yaluri N,
    4. Modi S,
    5. Kuusisto J,
    6. Laakso M
    . Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort. Diabetologia 2015;58:1109–17.
    OpenUrlCrossRefPubMed
  107. 107.↵
    1. Rissanen AM,
    2. Heliövaara M,
    3. Knekt P,
    4. Reunanen A,
    5. Aromaa A
    . Determinants of weight gain and overweight in adult Finns. Eur J Clin Nutr 1991;45:419–30.
    OpenUrlPubMedWeb of Science
  108. 108.↵
    1. Martin CK,
    2. Church TS,
    3. Thompson AM,
    4. Earnest CP,
    5. Blair SN
    . Exercise dose and quality of life: a randomized controlled trial. Arch Intern Med 2009;169:269–78.
    OpenUrlCrossRefPubMedWeb of Science
  109. 109.↵
    1. Franklin BA,
    2. Lavie CJ
    . Impact of statins on physical activity and fitness: ally or adversary? Mayo Clin Proc 2015;90:1314–9.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

The Journal of the American Board of Family     Medicine: 29 (6)
The Journal of the American Board of Family Medicine
Vol. 29, Issue 6
November-December 2016
  • Table of Contents
  • Table of Contents (PDF)
  • Cover (PDF)
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on American Board of Family Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Statin Therapy as Primary Prevention in Exercising Adults: Best Evidence for Avoiding Myalgia
(Your Name) has sent you a message from American Board of Family Medicine
(Your Name) thought you would like to see the American Board of Family Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
4 + 3 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Statin Therapy as Primary Prevention in Exercising Adults: Best Evidence for Avoiding Myalgia
N. John Bosomworth
The Journal of the American Board of Family Medicine Nov 2016, 29 (6) 727-740; DOI: 10.3122/jabfm.2016.06.160085

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Statin Therapy as Primary Prevention in Exercising Adults: Best Evidence for Avoiding Myalgia
N. John Bosomworth
The Journal of the American Board of Family Medicine Nov 2016, 29 (6) 727-740; DOI: 10.3122/jabfm.2016.06.160085
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Methods
    • Results
    • Discussion
    • Conclusions
    • Notes
    • References
  • Figures & Data
  • References
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Obstacles aux interventions cliniques liees a lactivite physique dans le traitement des maladies cardiometaboliques
  • Impediments to clinical application of exercise interventions in the treatment of cardiometabolic disease
  • Bread and Butter of Family Medicine: Guidelines, Population Screening, Diagnostic Evaluations, and Practice Models
  • Google Scholar

More in this TOC Section

  • Virtual Preconception Risk Assessment and Counseling In Primary Health Care
  • Shared Decision-Making and Discontinuation of Opioid Therapy for Chronic Pain
  • Blood Pressure Medication Side Effect Symptoms and Patient Treatment Satisfaction and Adherence
Show more Original Research

Similar Articles

Keywords

  • Aged
  • Exercise
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Muscles
  • Muscular Diseases
  • Myalgia
  • PubMed
  • Quality of Life

Navigate

  • Home
  • Current Issue
  • Past Issues

Authors & Reviewers

  • Info For Authors
  • Info For Reviewers
  • Submit A Manuscript/Review

Other Services

  • Get Email Alerts
  • Classifieds
  • Reprints and Permissions

Other Resources

  • Forms
  • Contact Us
  • ABFM News

© 2025 American Board of Family Medicine

Powered by HighWire